103 results about "Cellular composition" patented technology

The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differeentitation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and / or immunological features of non-hematopoietic cells; and uses of the cellular compositions. The invention also relates to a method for the expansion of hemtopoietic stem and progenitor cells.

A composite scaffold with a porous ceramic phase and a porous polymer phase. The polymer is foamed while in solution that is infused in the pores of the ceramic to create a interphase junction of interlocked porous materials. The preferred method for foaming is by lyophilization. The scaffold may be infused or coated with a variety of bioactive materials to induce ingrowth or to release a medicament. The multi-layered porous scaffold can mimic the morphology of an injured tissue junction with a gradient morphology and cell composition, such as articular cartilage.

A method of forming an array of viable cells is carried out by ink-jet printing a cellular composition containing said cells on a substrate. At least two different types of viable mammalian cells are printed on the substrate, the at least two different types of viable mammalian cells selected to together form a tissue. In some embodiments at least three or four different viable mammalian cells are printed on the substrate, the cells selected to together form a tissue. In some embodiments one of the viable mammalian cell types is a stem cell. In some embodiments the method further comprises printing at least one support compound on the substrate, the support compound selected to form a tissue together with said cells. In some embodiments the method further comprises printing at least one growth factor on the substrate, the growth factor selected to cause the cells to form a tissue.

This invention relates to a process for recognizing signatures in complex gene expression profiles that comprises the steps of: a) making available a biological sample that is to be examined, b) making available at least one suitable expression profile, whereby at least one expression profile comprises one or more markers that are typical exclusively of the expression profile, c) determining the complex expression profile of the biological sample, d) determining the quantitative cellular composition of the biological sample by means of the expression profiles determined in steps b) and c). In addition, the process according to the invention can comprise the steps of e) calculating a virtual signal that is expected based on the specific composition of the expression profile, f) calculation of the difference from the actually measured complex expression profile and the virtual signal, and g) determination of the quantitative composition of the complex expression profile based on the determined differences. In addition, this invention relates to the application of the process according to the invention in the diagnosis, prognosis and / or tracking of a disease. Finally, corresponding computer systems, computer programs, computer-readable data media and laboratory robots or evaluating devices for molecular detection methods are disclosed.

A platform of devices for removing obstructions and other objects within a blood vessel or other interior lumen of an animal is provided. The system may be deployed in the lumen from a catheter(s) and the system includes a proximal hub, and a distal basket comprised of a plurality of cells. A number of different baskets designs are disclosed. Methods of manufacturing such baskets out of a single tube of a memory metal without the need for any welding or soldering, and methods of use are also disclosed.

The present invention provides for cellular compositions which facilitate engraftment of hematopoietic stem cells from a syngeneic, allogeneic or xenogeneic donor. The cellular compositions of the invention facilitate engraftment while minimizing the risk of graft versus host disease in the graft recipient. According to a preferred embodiment of the invention, a cell composition is provided, which cell composition comprises hematopoietic stem cells, such as CD34+ cells and / or facilitating cells, in combination with αβ TCR+ T cells. The invention also relates to methods of using the cellular compositions of the invention to induce donor specific tolerance in a recipient, thus allowing the transplantation of donor organs, cells and tissues. Also disclosed are methods of treating leukemia and cancer as well as infectious diseases caused by viruses.

The present invention is directed to devices for repair, replacement or augmentation of soft tissues in an organism. The devices comprise cellular compositions comprising cells and preferably, structural proteins such as collagen or elastin. The devices can also be used in methods for testing the effects of agents on soft tissues.

A protocol-based ultrasound method is provided. The ultrasound method provides a template comprised of cells. Each of the cells contain scan parameters defining a scan sequence for acquisition of ultrasound images along one or more scan planes through an object. Prior to scanning the object, parameter values for the scan parameters associated with cells in the template are entered to define the scan sequences along at least two scan planes. The object is scanned with an ultrasound probe to automatically and successively acquire ultrasound images along at least two scan planes based on the parameter values for the scan parameters in the cells. The method displays ultrasound images of an object that is changing states in accordance with a protocol. Each of the ultrasound images is acquired along a corresponding scan plane through the object. A collection of ultrasound images is provided. Each of the ultrasound images is acquired along an associated scan plane while the object is in an associated state. The display is segmented into at least two quadrants. A corresponding ultrasound image is presented in the quadrants, wherein co-displayed ultrasound images correspond to one of a common state of the object and a common scan plane through the object.

A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cells by the host's immune response. At least one additional therapeutic factor is administered selected from the group consisting of a cell killing agent, a tumor penetration enhancer, a chemotherapeutic agent, antimicrobial agent, a cytotoxic immune cell, and a compound capable of stimulating an endogenous immune response wherein the compound does not bind to the ligand-immunogen conjugate.

The invention provides improved T cell compositions and methods for manufacturing T cells. More particularly, the invention provides methods of T cell manufacturing that result in adoptive T cell immunotherapies with improved survival, expansion, and persistence in vivo.

Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.

Oncolytic viruses can be used to purge cellular compositions to remove undesired neoplastic cells before the cellular compositions are used for transplantation. The present invention relates to the use of a virus to pre-treat a subject prior to delivery into the subject a transplant that has been purged with the same virus. This pre-treatment serves to elicit an immune response in the subject against the virus, thereby protecting the subject from infections by the virus after receiving the transplant, which likely contains infectious viruses.

The present invention is directed to a non-immunogenic cellular composition comprising: a cell having a cell surface and antigenic determinants on the cell surface; an optional linker molecule covalently attached to the cell surface; and a hydrophilic, biocompatible, non-immunogenicity providing compound or polymer (e.g., polyethylene glycol or a derivative thereof) covalently attached to the linker molecule or directly to the cell. In one embodiment, the linker molecule is covalently attached directly to the antigenic determinant on the cell surface. In an alternate embodiment, the linker molecule may be covalently attached to a non-antigenic site on the cell surface, but will camouflage the antigenic determinant on the cell surface. Various uses of the resulting non-immunogenic cell are also provided, including a method of decreasing phagocytosis of a cell, a method of decreasing an adverse reaction to a transfusion, a method of decreasing rejection of a transplanted cell, tissue or organ, and a method of decreasing antibody-induced aggregation of cells.

Multi-modal approaches to predict tumor immune infiltration are based on integrating gene expression data and imaging features in a neural network-based framework. This framework is configured to estimate percent composition, and thus immune infiltration score, of a patient tumor biopsy sample. Multi-modal approaches may also be used to predict cell composition beyond immune cells via integrated multi-layer neural network frameworks.

A microfluidic device provides high throughput generation and analysis of defined three-dimensional cell spheroids with controlled geometry, size, and cell composition. The cell spheroids of the invention mimic tumor microenvironments, including pathophysiological gradients, cell composition, and heterogeneity of the tumor mass mimicking the resistance to drug penetration providing more realistic drug response. The device is used to test the effects of antitumor agents.

Disclosed herein are cellular compositions, stable continuous cell cultures, reporter cell lines, pharmaceutical preparations, cell penetrable pluripotent stem cells transcription factors and methods related thereto, related to reprogrammed somatic cells.

Non-hemolytic cytolytic agents selected from peptides, complexes of bundled peptides, mixtures of peptides or random peptide copolymers have a selected cytolytic activity manifested in that they have a cytolytic activity on pathogenic cells, being cells which are non-naturally occurring with the body consisting of microbial pathogenic organisms and malignant cells; and are non-hemolytic, having no cytolytic effect on red blood cells. The peptides may be cyclic derivatives of natural peptides such as pardaxin and mellitin and fragments thereof in which L-amino acid residues are replaced by corresponding D-amino acid residues, or are diastereomers of linear peptides composed of varying ratios of at least positively charged amino acid and at least one hydrophobic amino acid, and in which at one of the amino acid residues is a D-amino acid. Pharmaceutical compositions comprising the non-hemolytic cytolytic agents can be used for the treatment of several diseases caused by pathogens including antibacterial, fungal, viral mycoplamsa and protozoan infections and for the treatment of cancer.

The present invention provides a therapeutic composition comprising:(i) Trolox, Na+, K+, Ca2+, Mg2+, Cl−, H2PO4−, HEPES, lactobionate, sucrose, mannitol, glucose, dextran-40, adenosine, glutathione; and(ii) stem cells or progenitor cells,wherein the composition does not comprise a dipolar aprotic solvent, in particular DMSO.The present invention also relates to methods of formulating said composition for cryopreservation and subsequent direct administration to a patient, and medicaments comprising said composition.

Disclosed are methods for differential extraction of a target component from a sample which is predominantly composed of other types of non-target cells that can be lysed using methods that do not lyse the target cells, so that the target material can be purified away from the lysed non-target material. One exemplary method is directed to isolating sperm cells from an aqueous sample and kits for performing same.

It is an object of the present invention to provide: a method for preparing a cell concentrate which efficiently separates nucleated cells from unnecessary cells contained in a cell-containing solution by simple operations, thereby reducing the volume of a solution used for cryopreservation that contains the nucleated cells, when the cell-containing solution that contains the nucleated cells and the unnecessary cells has been filtrated with a filter device and when a recovery solution is then introduced into the filter device to recover the nucleated cells captured by a filter material; and a cell composition. The present invention provides a method for preparing a cell concentrate, which comprises: introducing a cell-containing solution that contains nucleated cells and unnecessary cells into a filter device comprising a filter material for substantially capturing the nucleated cells and for substantially giving passage to the unnecessary cells, so as to capture the nucleated cells by the above-described filter material and to discharge the unnecessary cells from the above device; and introducing a recovery solution into the above-described filter device, so as to recover the nucleated cells captured by the above-described filter material, wherein the above-described method is characterized in that the cell-containing solution that contains nucleated cells and unnecessary cells are separated into a layer that is rich in nucleated cells and a layer that is rich in unnecessary cells, the layer rich in unnecessary cells is first introduced into the above-described filter device, and the layer rich in nucleated cells is then introduced therein, so as to discharge the unnecessary cells remaining in the above-described filter device while capturing the nucleated cells by the above-described filter material, and a recovery solution is then introduced into the above-described filter device, so as to recover the nucleated cells captured by the above-described filter material.

The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention.

The present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.

The present invention includes a method and apparatus to transplant functional cells into failing heart muscle to cure heart disease. In particular, the present invention relates to a method and apparatus to deliver cell-composed medical device and / or three-dimensional cell composite per minimally invasive intracornonary approach to the infarct-related artery, allowing functional cells to home in and engraft to the zone of the infarct and peri-infarct tissue, in order to regenerate infarcted, scarred or non-functioning myocardial tissue into functioning muscle (“myogenesis”), also to create growth and proliferation of new blood vessel (“angiogenesis”) in the area.